bioAffinity Technologies Inc. Warrant (BIAFW)
$0.08
As on 24-Aug-2026 11:04EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-16.86 Mln
EBITDA
$-24.93 Mln
Net Profit
$-32.99 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
bioAffinity Technologies Inc. Warrant (BIAFW)
| -78.5 | -14.2 | -62.5 | 7.3 | -37.0 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
bioAffinity Technologies Inc. Warrant (BIAFW)
| 4.0 | 291.2 | -79.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout bioAffinity Technologies Inc. Warrant (BIAFW)
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates... through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas. Read more
-
Founder & Executive Chairman of the Board
Mr. Steven Girgenti
-
Founder & Executive Chairman of the Board
Mr. Steven Girgenti
-
Headquarters
San Antonio, TX
-
Website
FAQs for bioAffinity Technologies Inc. Warrant (BIAFW)
What is the current share price of bioAffinity Technologies Inc Warrant (BIAFW) Today?
The share price of bioAffinity Technologies Inc Warrant (BIAFW) is $0.08 (NASDAQ) as of 24-Aug-2026 11:04 EDT. bioAffinity Technologies Inc Warrant (BIAFW) has given a return of -37.05% in the last 3 years.
What is the current PB & PE ratio of bioAffinity Technologies Inc Warrant (BIAFW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.04 |
0.08 |
2024 |
-0.02 |
0.05 |
2023 |
-0.10 |
0.17 |
2022 |
-0.01 |
0.01 |
2021 |
-- |
-- |
What is the 52 Week High and Low of bioAffinity Technologies Inc Warrant (BIAFW)?
The 52-week high and low of bioAffinity Technologies Inc Warrant (BIAFW) are Rs 0.81 and Rs 0.05 as of 28-Aug-2026.
What is the market cap of bioAffinity Technologies Inc Warrant (BIAFW)?
bioAffinity Technologies Inc Warrant (BIAFW) has a market capitalisation of -- as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in bioAffinity Technologies Inc Warrant (BIAFW)?
Before investing in bioAffinity Technologies Inc Warrant (BIAFW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.